Lunai Bioworks Inc
NASDAQ:LNAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lunai Bioworks Inc
NASDAQ:LNAI
|
US |
|
Bell Food Group AG
SIX:BELL
|
CH |
|
Medivolve Inc
OTC:MEDVF
|
CA |
|
Orix JREIT Inc
TSE:8954
|
JP |
|
ICL Group Ltd
TASE:ICL
|
IL |
|
G
|
GameOn Entertainment Technologies Inc
CNSX:GET
|
CA |
|
D
|
Demco PCL
SET:DEMCO
|
TH |
|
M
|
Mastech Digital Inc
AMEX:MHH
|
US |
|
Vital Ltd
NZX:VTL
|
NZ |
|
F
|
Firering Strategic Minerals Plc
LSE:FRG
|
CY |
|
Serviceware SE
XETRA:SJJ
|
DE |
|
Coterra Energy Inc
NYSE:CTRA
|
US |
|
Methanor SCA
PAR:ALMET
|
FR |
|
PubMatic Inc
NASDAQ:PUBM
|
US |
|
Hunan Sokan New Materials Co Ltd
SSE:688157
|
CN |
|
F
|
Four Seas Mercantile Holdings Ltd
HKEX:374
|
HK |
|
I
|
Intersect Ent Inc
F:7IN
|
US |
|
N
|
Novoray Corp
SSE:688300
|
CN |
|
C
|
Camanchaca SA
SGO:CAMANCHACA
|
CL |
|
T
|
Tion Renewables AG
XETRA:TION
|
DE |
|
TYK Corp
TSE:5363
|
JP |
|
R
|
Resilux NV
LSE:0FSN
|
BE |
|
D
|
Duong Hieu Trading and Mining JSC
VN:DHM
|
VN |
|
Solvar Ltd
ASX:SVR
|
AU |
Lunai Bioworks Inc
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
